AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.
PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
Patients with narrowing of at least 50% in three major coronary arteries did equally well when treated with a minimally invasive stent placement guided either by ultrasound-based imaging or by a novel ...
which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today’s patients. Data were presented at the American College of ...
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...
The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...
This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...
March 25, 2025 – The FDA has approved a new treatment for adults with a life-threatening heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a rare but serious ...
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback